伴侶動物關節炎市場、機會、成長動力、產業趨勢分析與預測，2024-2032

全球伴侶動物關節炎市場到 2023 年價值約 34 億美元，2024 年至 2032 年複合年成長率將達到 7.2%。這種成長刺激了對伴侶動物保健產品的需求，包括藥物和補充劑。美國寵物產品協會的全國寵物主人調查顯示，約 8,690 萬個美國家庭（即 66%）擁有寵物，從鳥類、貓到狗和雪貂。此外，全球收養寵物的增加，加上先進診斷工具和更有效的治療選擇等獸醫技術的進步，推動了市場的成長。這些進步提高了治療效果並擴大了可治療疾病的範圍。

獸醫診所擴大利用先進的影像技術，例如 MRI（磁振造影）和 CT（電腦斷層掃描）掃描來診斷寵物的關節問題。這些工具使獸醫能夠更清晰地了解關節結構，從而製定更精確的治療計劃。此外，市場由創新的治療技術和設備驅動，包括雷射治療、客製化復健計畫和活動監視器。

整個伴侶動物關節炎行業根據治療類型、疾病類型、動物類型、最終用途和地區進行細分。

市場按治療類型分為藥物、食品補充劑、手術和其他治療。到 2023 年，藥品領域預計將達到 15 億美元。為了減輕伴侶動物的關節炎症狀，獸醫通常會開一些藥物，如非類固醇抗發炎藥、皮質類固醇和緩解疾病的骨關節炎藥物 (DMOAD)，強調緩解疼痛和減少發炎。獸醫學的進步——從增強的診斷到強力的藥物和整體治療方案——提高了關節炎治療的有效性和可及性。

按疾病類型細分，伴侶動物關節炎市場包括骨關節炎、類風濕性關節炎和其他形式。 2023年，骨關節炎以64.3%的佔有率引領市場。骨關節炎在寵物中普遍存在，影響近 20% 的老年狗和貓，導致關節軟骨退化和隨後的骨骼變化。消費者對天然和整體療法（例如葡萄糖胺、軟骨素和 omega-3 脂肪酸等營養保健品）的傾向不斷上升，這表明對治療狗骨關節炎的產品的需求上升，從而推動市場成長。

2023 年，北美在全球伴侶動物關節炎市場中佔據主導地位，佔 45.6% 的佔有率，預測顯示該市場將持續強勁成長。北美市場擴張的主要驅動力包括寵物擁有量的激增、動物健康意識的提高以及獸醫護理的進步。隨著寵物護理領域的發展，北美利益相關者——尤其是那些創新和滿足獨特市場需求的利益相關者——有望獲得重大收益。

目錄

第 1 章：方法與範圍

第 2 章：執行摘要

第 3 章：產業洞察

• 產業生態系統分析
• 產業影響力
  • 成長動力
    • 收養寵物的趨勢不斷上升
    • 伴侶動物關節炎治療的技術創新
    • 老年寵物關節炎盛行率增加
  • 產業陷阱與挑戰
    • 與先進的診斷、藥物和專門治療相關的高成本
    • 研究和開發有限
• 成長潛力分析
• 技術景觀
• 監管環境
• 波特的分析
• PESTEL分析

第 4 章：競爭格局

• 介紹
• 公司市佔率分析
• 公司矩陣分析
• 主要市場參與者的競爭分析
• 競爭定位矩陣
• 戰略展望矩陣

第 5 章：市場估計與預測：按治療類型，2021 - 2032 年

• 主要趨勢
• 藥物
  • 非類固醇抗發炎藥
  • 單株抗體
  • 其他藥物
• 食品補充劑
• 手術
• 其他治療類型

第 6 章：市場估計與預測：按疾病類型，2021 - 2032 年

• 主要趨勢
• 骨關節炎
• 類風濕關節炎
• 其他關節炎類型

第 7 章：市場估計與預測：按動物類型，2021 - 2032

• 主要趨勢
• 狗
• 貓
• 其他動物

第 8 章：市場估計與預測：按最終用途，2021 - 2032 年

• 主要趨勢
• 獸醫院
• 獸醫診所
• 獸醫復健中心
• 其他最終用戶

第 9 章：市場估計與預測：按地區分類，2021 - 2032 年

• 主要趨勢
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 英國
  • 法國
  • 西班牙
  • 義大利
  • 荷蘭
  • 歐洲其他地區
• 亞太地區
  • 日本
  • 中國
  • 印度
  • 澳洲
  • 韓國
  • 亞太地區其他地區
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
  • 拉丁美洲其他地區
• 中東和非洲
  • 南非
  • 沙烏地阿拉伯
  • 中東和非洲其他地區

第 10 章：公司簡介

• American Regent, Inc.
• Bayer AG (Bayer Animal Health)
• Boehringer Ingelheim International GmbH
• CEVA Sante Animale
• Dechra Pharmaceuticals plc
• Elanco
• Eltech K-Laser s.r.l.
• Medivet
• Norbrook laboratories
• Nutramax Laboratories Veterinary Sciences, Inc
• Vetoquinol SA
• Vibrac
• Zoetis, Inc.

The Global Companion Animal Arthritis Market, valued at approximately USD 3.4 billion in 2023, is set to grow at a CAGR of 7.2% from 2024 to 2032. Increasing pet ownership is a primary driver for the market's growth. This rise has spurred demand for healthcare products for companion animals, including medications and supplements. The National Pet Owners Survey by the American Pet Products Association reveals that around 86.9 million American families, or 66%, own pets, spanning from birds and cats to dogs and ferrets. Moreover, the global uptick in pet adoption, coupled with technological strides in veterinary medicine-like advanced diagnostic tools and more potent treatment options-fuels market growth. These advancements boost treatment efficacy and expand the range of treatable conditions.

Veterinary clinics are increasingly utilizing advanced imaging techniques, such as MRI (magnetic resonance imaging) and CT (computed tomography) scans, to diagnose joint issues in pets. These tools offer veterinarians a clearer view of joint structures, allowing for more precise treatment plans. Furthermore, the market is driven by innovative therapeutic technologies and devices, including laser treatments, tailored rehabilitation programs, and activity monitors.

The overall companion animal arthritis industry is segmented based on treatment type, disease type, animal type, end-use, and region.

The market is segmented by treatment type into medication, food supplements, surgery, and other treatments. In 2023, the medication segment is projected to account for USD 1.5 billion. To alleviate arthritis symptoms in companion animals, veterinarians commonly prescribe pharmaceutical drugs like NSAIDs, corticosteroids, and disease-modifying osteoarthritis drugs (DMOADs), emphasizing pain relief and inflammation reduction. Advancements in veterinary medicine-ranging from enhanced diagnostics to robust medications and holistic treatment protocols-have improved the effectiveness and accessibility of arthritis treatments.

Segmented by disease type, the companion animal arthritis market includes osteoarthritis, rheumatoid arthritis, and other forms. In 2023, osteoarthritis led the market with a commanding 64.3% share. Osteoarthritis, prevalent in pets, impacts nearly 20% of older dogs and cats, leading to joint cartilage degeneration and subsequent bone changes. The rising consumer inclination towards natural and holistic remedies-like nutraceuticals such as glucosamine, chondroitin, and omega-3 fatty acids-signals an uptick in demand for products addressing osteoarthritis in dogs, thus propelling market growth.

North America held a dominant 45.6% share of the global companion animal arthritis market in 2023, with forecasts suggesting continued robust growth. Key drivers for North America's market expansion include surging pet ownership, increased awareness of animal health, and advancements in veterinary care. As the pet care landscape evolves, North American stakeholders-especially those innovating and addressing unique market needs-are poised for significant gains.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
    • 1.5.1.1 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising trend of pet adoption
    • 3.2.1.2 Technological innovation in treatments of arthritis for companion animals
    • 3.2.1.3 Increasing prevalence of arthritis in aging pets
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High costs associated with advanced diagnostics, medications, and specialized treatments
    • 3.2.2.2 Limited research and development
• 3.3 Growth potential analysis
• 3.4 Technological landscape
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy outlook matrix

Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Medication
  • 5.2.1 NSAIDs
  • 5.2.2 Monoclonal antibodies
  • 5.2.3 Other medications
• 5.3 Food supplement
• 5.4 Surgery
• 5.5 Other treatment types

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Osteoarthritis
• 6.3 Rheumatoid arthritis
• 6.4 Other arthritis types

Chapter 7 Market Estimates and Forecast, By Animal Type, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Dogs
• 7.3 Cats
• 7.4 Other animals

Chapter 8 Market Estimates and Forecast, By End-Use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Veterinary hospitals
• 8.3 Veterinary clinics
• 8.4 Veterinary rehabilitation centers
• 8.5 Other end-users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
  • 9.3.7 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 Japan
  • 9.4.2 China
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Rest of Asia Pacific
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
  • 9.5.4 Rest of Latin America
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 Rest of Middle East and Africa

Chapter 10 Company Profiles

• 10.1 American Regent, Inc.
• 10.2 Bayer AG (Bayer Animal Health)
• 10.3 Boehringer Ingelheim International GmbH
• 10.4 CEVA Sante Animale
• 10.5 Dechra Pharmaceuticals plc
• 10.6 Elanco
• 10.7 Eltech K-Laser s.r.l.
• 10.8 Medivet
• 10.9 Norbrook laboratories
• 10.10 Nutramax Laboratories Veterinary Sciences, Inc
• 10.11 Vetoquinol SA
• 10.12 Vibrac
• 10.13 Zoetis, Inc.